PG 116800

Drug Profile

PG 116800

Alternative Names: PG 530742

Latest Information Update: 06 Apr 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Procter & Gamble
  • Class Heart failure therapies; Hydroxamic acids
  • Mechanism of Action Metalloprotease inhibitors; Metalloprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Heart failure; Osteoarthritis

Most Recent Events

  • 18 Apr 2005 Data presented at the 54th Annual Scientific Sessions of the American College of Cardiology (ACC-2005) have been added to the Adverse events and Heart Failure pharmacodynamics sections
  • 17 Mar 2004 Data presented at the 53rd Annual Scientific Sessions of the American College of Cardiology (ACC-2004) have been added to the Heart Failure pharmacodynamics section
  • 31 Aug 2003 Phase-II clinical trials in Heart failure in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top